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http:WHAT THIS PAPER ADDS
Patients with repaired aortic aneurysms have been previously shown to have a greater burden of cardiovascular
risk and comorbidity than the wider population, with an associated shortfall in relative long-term survival. This
study reports contemporary data describing the long-term incidence of mortality and adverse cardiovascular
events in patients discharged from hospital after surviving aortic aneurysm repair. Five-year mortality and
adverse events were signiﬁcantly more common in patients with aneurysms than control participants. Contrary
to recent assertions, long-term survival remains poor after aneurysm repair and adverse cardiovascular events
are common relative to the wider population.Objective: To report the contemporary life expectancy of patients undergoing abdominal (AAA) or thoracic aortic
aneurysm (TAA) repair in England, relative to a healthy control population.
Methods: A retrospective observational caseecontrol study was carried out of Hospital Episode Statistics (HES)
data, an administrative dataset covering the entire English National Health Service. Patients undergoing elective
repair of an abdominal or thoracic aortic aneurysm in an English NHS hospital between April 2006 and March
2011 were included. Outcome measures were 5-year all-cause mortality (in- and out-of-hospital) and adverse
cardiovascular events (myocardial infarction, stroke, emergency amputation or limb revascularisation).
Results: 19,505 AAA and 730 TAA repairs were identiﬁed, with 75,260 and 2,721 control participants,
respectively, and 27.5 (1.0e60.0) months’ median (range) follow-up. Five-year survival was 67.4% for AAA against
81.1% for control participants, and 65.3% for TAA against 89.1% for control participants (p < .001). Freedom from
adverse cardiovascular events was 86.1% for AAA against 93% for control participants and 89.1% for TAA against
94.4% for control participants (p < .001).
Conclusion: Long-term survival remains poor after aneurysm repair and adverse cardiovascular events are
common relative to the wider population. Further research is required to characterise and optimise
cardiovascular risk prevention in patients with aortic aneurysms.
 2013 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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It has previously been reported that the long-term survival of
patients who underwent abdominal aortic aneurysm (AAA)
repair was considerably poorer than age- and gender-
matched control participants in the wider population.1,2
This discrepancy was largely attributable to the excessrresponding author. S.S. Bahia, St George’s Vascular Institute, Room
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//dx.doi.org/10.1016/j.ejvs.2013.09.008cardiovascular risk of patients with aneurysms,3 and subop-
timal management of cardiovascular risk factors may have
been partly responsible for the high mortality. The impor-
tance of aggressive intervention in at-risk patients has been
illustrated by level 1 evidence, that goal-directed medical
therapy signiﬁcantly improved survival in diabetic patients.4
The cardiovascular risk proﬁle of patients with AAA or
thoracic aortic aneurysms (TAA) potentially represents an
equivalent opportunity for focussed medical therapy to
improve life expectancy. However, it is not known whether
the shortfall in survival that has been previously demon-
strated for AAA persists in contemporary practice, with
modern management of cardiovascular risk factors.
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tancy after AAA repair might have improved, with survivors
of AAA attaining 90% of the expected survival of otherwise
comparable Swedish citizens.5 Earlier evidence of poor
survival after AAA or TAA repair may not be applicable to
modern patients, and concerns with previous studies
include small sample size and limited scientiﬁc quality.2 The
epidemiology of AAA has been improved by modern trends
in smoking behaviour, public health measures, and im-
provements in cardiovascular risk management.6 It is
conceivable that these factors may also have improved the
long-term survival of patients who have undergone aneu-
rysm repair compared with the general population.
The life expectancy of patients surviving AAA or TAA
repair therefore requires focused re-appraisal and compar-
ison with the general population, to clarify whether modern
medical therapy and the effects of health policy have
reduced the shortfall in long-term survival that was
observed after aneurysm repair. The objective of this study
was to quantify the difference in survival and cardiovascular
morbidity between patients surviving repair of AAA or TAA
with a control population, using a large contemporary
dataset.METHODS
Demographic and in-hospital outcome data were extracted
from English Hospital Episode Statistics for patients under-
going elective open repair (OR) or endovascular repair
(EVAR/TEVAR) of AAA or TAA in England between April 1,
2006 and March 31, 2011. These data were linked to mor-
tality records from the Ofﬁce of National Statistics (ONS) to
track long-term survival. The admission on which the pro-
cedure was performed was termed the index admission for
the purposes of this study.
AAA repairs were identiﬁed according to previously
published methodology.7e9 With regard to TAA repairs, it
was assumed that aneurysmal disease was limited to the
descending thoracic aorta because patients who were
known to have undergone ascending aortic intervention
were identiﬁed and excluded (OPCS-4 code L19.1: replace-
ment of aneurysmal segment of ascending aorta by anas-
tomosis of aorta to aorta). A minimum age of 50 years was
used to exclude those with congenital aortic disease. The
full list of diagnostic and procedural codes used for identi-
ﬁcation of TAA is given in the supplementary material
accompanying this manuscript. Only patients discharged
alive after the index AAA or TAA repair were included in
analysis, to negate the early procedural mortality attribut-
able to surgical intervention.
A matched control participants was obtained for each
patient undergoing TAA or AAA repair, by selecting pa-
tients who underwent elective inguinal hernia repair, total
knee, or total hip arthroplasty with the same date of
operation, health authority, age, gender, and social
deprivation as each AAA/TAA. Hernia repair and total hip
or knee arthroplasty were chosen as control conditions
because these procedures have negligible in-hospital ordisease-speciﬁc mortality; the patients can therefore be
considered representative of the broader population who
are ﬁt for elective surgery but without aneurysmal disease.
The procedural codes to identify elective inguinal hernia
repair, total knee and total hip arthroplasty are listed
in the supplementary material accompanying this
manuscript.
The primary outcome measures were in- and out-of-
hospital all-cause mortality (excluding the index admis-
sion), adverse cardiovascular events (ACE), and a composite
measure of all-cause mortality or ACE. An ACE was deﬁned
as an in-patient admission for stroke, myocardial infarction,
aortoiliac or peripheral arterial thrombosis or embolism,
emergency amputation or open/endovascular lower limb
revascularisation. Sensitivity analyses were performed for
octogenarian and non-octogenarian patients because the
repair of AAA in patients over 80 years of age has attracted
focussed study; careful consideration is given to life ex-
pectancy after aneurysm exclusion in octogenarians.10,11
For identifying outcomes, the International Classiﬁcation
of Diseases-10 (ICD-10) codes used were I21 and I22 for
myocardial infarction, and I63, I64, I69.4, and I69.8 for
stroke. Aortoiliac and peripheral embolism, emergency
amputation, and lower limb revascularisation were deﬁned
and extracted according to previous methodology.12,13
Models were risk-adjusted for the pre-existing comorbidity
of AAA/TAA patients and control participants, identiﬁed
using the Royal College of Surgeons Charlson score meth-
odology for administrative data,14 and categorised as prior
myocardial infarction, congestive cardiac failure, peripheral
vascular disease, cerebrovascular disease, chronic pulmo-
nary disease, diabetes mellitus, renal disease, dementia, or
previous malignancy.
The HES is the administrative dataset for the English
National Health Service (NHS), which contains information
regarding every admission of a patient to an NHS hospital.
HES data are pseudonymised by the allocation of a unique
identiﬁer to each patient, so individuals can be tracked as
their care moves from consultant to consultant (episodes)
on any particular admission, and between hospital admis-
sions (spells). The dataset therefore allows individual pa-
tients to be followed with respect to multiple hospital
admissions. This feature is unique to the HES data over
administrative datasets from other countries, which do not
have a facility for long-term follow-up. The Ofﬁce for Na-
tional Statistics (ONS) is an independent, executive ofﬁce of
the UK Statistics Authority, which records the date of all
deaths in the UK matched to individual demographic data.
This includes deaths both in and out of hospital. The date of
death of each patient recorded in the ONS registry is linked
to the patient’s individual HES identiﬁer. This allowed long-
term outcomes to be quantiﬁed for the present cohort in
terms of “in” and “out” of hospital deaths. Each patient was
matched against ONS records to identify any recorded date
of death for 5 years following the index admission.15 Owing
to the uncertainty regarding aortic-related deaths, as few
patients undergo autopsy in the UK, only all-cause mortality
was reported in this study.
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KaplaneMeier analysis was used to report freedom from
death, ACE, or a composite endpoint of death or ACE.
Subgroup comparison was performed by log-rank test, with
Sidak adjustment for multiple comparisons. Conditional lo-
gistic regression was used to generate adjusted odds ratios
with 95% conﬁdence intervals for the prevalence of speciﬁc
comorbidities in patients with AAA/TAA compared with
matched control participants. Signiﬁcant results were re-
ported from the model at a level of a ¼ .05.
Cox proportional hazards models were ﬁtted for analysis
of mortality after AAA or TAA repair, including consideration
of gender, age on index admission, quintiles of social
deprivation, patient type (case or control), strategic health
authority (SHA), year of surgery, and comorbidity, with
interaction terms for the relation between comorbidity and
patient type, SHA and patient type, gender and patient type
and year of surgery with patient type. Stepwise selection
procedures were used, with comparison of models by
Akaike’s Information Criterion (AIC) to ascertain whether
individual covariates improved goodness-of-ﬁt. Inclusion in
the model required a signiﬁcance level of a ¼ .1, and sig-
niﬁcant results were reported at a ¼ .05. All analyses were
performed using SAS version 9.1 (SAS Institute Inc., Cary,
NC, USA).RESULTS
Patients were identiﬁed as 19,505 AAA and 730 TAA repairs,
with 75,260 and 2,721 control participants, respectively.
Median (range) follow-up was 27.52 (1.02e59.97) months.
Control participants were successfully derived with
matched gender, social deprivation, and age for each AAA/Table 1. Comorbidity for AAA cases, AAA control participants, TAA ca
Surgeons Charlson Index criteria.14
Comorbidity AAA cases
Prior myocardial infarction (%) 15.4
Prior congestive cardiac failure (%) 10.5
Renal disease (%) 12.2
Cerebrovascular disease (%) 8.7
Diabetes mellitus (%) 13.6
Previous malignancy(%) 14.5
Dementia (%) 0.9
Chronic obstructive pulmonary
disease (%)
22
Comorbidity TAA cases T
p
Prior myocardial infarction (%) 10
Prior congestive cardiac failure (%) 15.6
Renal disease (%) 12.1
Cerebrovascular disease (%) 12.7
Diabetes mellitus (%) 9.6 1
Previous malignancy(%) 8
Dementia (%) 0.8
Chronic obstructive pulmonary
disease (%)
27 1TAA, and underwent surgery in the same hospitals as AAA
or TAA cases at the time of the index operation.
Age and comorbidity
The mean (SD) ages of patients undergoing open AAA
repair, EVAR, open TAA repair and TEVAR were 72.36 (7.08),
75.09 (7.15), 68.08 (8.16), and 70.15 (8.44), years, respec-
tively. Patients with AAA were signiﬁcantly more likely to
have a history of prior myocardial infarction (OR 2.78, 95%
CI 2.65 to 2.92), congestive cardiac failure (OR 2.31, 95% CI
2.19 to 2.45), renal disease (OR 3.27, 95% CI 3.08 to 3.46),
cerebrovascular disease (OR 2.27, 95% CI 2.13 to 2.42),
diabetes (OR 1.35, 95% CI 1.29 to 1.42), previous malig-
nancy (OR 1.88, 95% CI 1.8 to 1.98), and chronic obstructive
pulmonary disease (OR 1.69, 95% CI 1.63 to 1.76) than
control participants (p < .0001 for all comparisons). There
was no difference in the rate of dementia (p ¼ .2267)
(Table 1).
Patients with TAA were signiﬁcantly more likely to have a
history of prior myocardial infarction (OR 2.65, 95% CI 1.88
to 3.73), congestive cardiac failure (OR 4.39, 95% CI 3.24 to
5.95), renal disease (OR 3.37, 95% CI 2.45 to 4.64), cere-
brovascular disease (OR 4.73, 95% CI 3.35 to 6.69), and
chronic obstructive pulmonary disease (OR 2.16, 95% CI
1.75 to 2.67) than control participants (p < .0001 for all
comparisons) (Table 1). There was no difference in the
incidence of diabetes (p ¼ .771), previous malignancy
(p ¼ .623), or dementia (p ¼ .426) between groups
(Table 1).
All-cause mortality
Survival after AAA repair was lower than in control partic-
ipants at 1, 3, and 5 years after the index operation (93.6%ses, and TAA control participants, derived using Royal College of
AAA control
participants
p OR (95% CI)
6.2 <.0001 2.78 (2.65 to 2.92)
4.8 <.0001 2.31 (2.19 to 2.45)
4.2 <.0001 3.27 (3.08 to 3.46)
4 <.0001 2.27 (2.13 to 2.42)
10.5 <.0001 1.35 (1.29 to 1.42)
8.4 <.0001 1.88 (1.8 to 1.98)
1 .1365 0.88 (0.75 to 1.04)
14.4 <.0001 1.69 (1.63 to 1.76)
horacic control
articipants
p OR (95% CI)
4.1 <.0001 2.65 (1.88 to 3.73)
4.4 <.0001 4.39 (3.24 to 5.95)
4.2 <.0001 3.37 (2.45 to 4.64)
3.1 <.0001 4.73 (3.35 to 6.69)
0.1 .7712 0.96 (0.72 to 1.28)
7.1 .6232 1.09 (0.78 to 1.51)
0.7 .4226 1.52 (0.54 to 4.3)
4.8 <.0001 2.16 (1.75 to 2.67)
Figure 2. Freedom from mortality in non-octogenarians and
octogenarians.
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control participants, p < .0001). Survival after TAA repair
was also poorer than in control participants at 1, 3, and 5
years after the index operation (89.6% vs. 98.3%, 78.7% vs.
93.8%, and 65.3% vs. 89.1%, TAA vs. control participants,
p < .0001) (Fig. 1).
Survival was signiﬁcantly lower after AAA and TAA repair
than in control participants, and after TAA repair than AAA
repair, for both octogenarian (p < .0001) and non-
octogenarian (p < .0001) subgroups (Fig. 2).
Adverse cardiovascular events
Patients with AAA had lower freedom from adverse car-
diovascular events than control participants at 1, 3, and 5
years after surgery (95.3% vs. 98.7%, 90.2% vs. 95.9%,
86.1% vs. 93%, p < .001). The same relationship was
observed between TAA repair and control participants at 1,
3, and 5 years after the index operation (94.1% vs. 99%,
90.6% vs. 96.6%, and 89.1% vs. 94.4%, p < .001) (Fig. 3).
Freedom from adverse cardiovascular events was signif-
icantly lower after AAA repair than in control participants
for both octogenarian (p < .0001) and non-octogenarian
(p < .0001) subgroups (Fig. 4). Patients undergoing non-
octogenarian TAA repair had signiﬁcantly lower freedom
from ACE than control participants (p < .0001) but there
was no difference in freedom from ACE between octoge-
narian TAA repairs and control participants (p ¼ .5066).
Mortality and adverse cardiovascular events
Freedom from a composite endpoint of death or ACE was
lower after AAA repair than after the control operations
(freedom from death or ACE 90.1% vs. 96.5%, 75.8% vs.
88% and 60.3% vs. 77.1% in AAA vs. control participants at
1, 3, and 5 years after surgery, p < .001). Freedom from the
composite endpoint was also lower after TAA repair than in
control participants (84.9% vs. 97.4%, 71.6% vs. 91.6%,
60.1% vs. 85.1% at 1, 3, and 5 years, p < .001) (Fig. 5).Figure 1. Freedom from mortality in AAA, TAA, and control
participants.
Figure 3. Freedom from adverse cardiovascular events in AAA,
TAA, and control participants.
Figure 4. Freedom from adverse cardiovascular events in non-
octogenarians and octogenarians.
Figure 5. Freedom from adverse cardiovascular events or
mortality.
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AAA repair than control participants in subgroup analysis of
both octogenarians (p < .0001) and non-octogenarians
(p < .0001) (Fig. 6). After TAA repair, non-octogenarians
had signiﬁcantly lower freedom from mortality or ACE
than control participants (p < .0001), but there was no
signiﬁcant difference between TAA repair patients and
control participants in the octogenarian subgroup
(p ¼ .464).Cox proportional hazards model for survival after AAA or
TAA repair
Multivariate analysis of 5-year survival in AAA patients and
control participants, demonstrated that the case/control
classiﬁcation of a patient (in the AAA repair group rather
than the control group) was an independent risk factor for
mortality in women but not men (Table 2). There was a
signiﬁcant interaction between the case/control variable
and gender; the discrepancy between AAA cases and con-
trol participants was greater for female patients, but withinFigure 6. Freedom from adverse cardiovascular events or mortality
in non-octogenarians and octogenarians.
Table 2. Cox proportional hazards model for 5-year all-cause
mortality in AAA patients and AAA control participants.
Covariate Hazard ratio
(>1 indicating
death is
more likely)
95% CI p
Age 1.085 1.081 to 1.088 <.0001
Gender <.0001
AAA (case vs. control) <.0001
Interaction: (case vs. control)*(Gender) .0002
Males:
AAA vs. control
participants
1.07 0.884 to 1.294 NS
Females:
AAA vs. control
participants
1.352 1.171 to 1.56 <.0001
Control participants:
males vs. females
1.293 1.198 to 1.396 <.0001
AAA:
males vs. females
1.024 0.884 to 1.185 NS
Comorbidity
Myocardial
infarction
1.1377 1.067 to 1.214 <.0001
Congestive cardiac
failure
1.7123 1.608 to 1.828 <.0001
Peripheral vascular
disease
1.5576 1.42 to 1.709 <.0001
Cerebrovascular
disease
1.2563 1.167 to 1.355 <.0001
Dementia 2.8490 2.532 to 3.215 <.0001
Chronic pulmonary
disease
1.5748 1.502 to 1.656 <.0001
Rheumatological
disease
1.3812 1.247 to 1.529 <.0001
Liver disease 1.8484 1.582 to 2.16 <.0001
Diabetes mellitus 1.1976 1.127 to 1.271 <.0001
Renal disease 1.5625 1.46 to 1.669 <.0001
Any malignancy 1.8797 1.776 to 1.988 <.0001
Metastatic solid
tumour
2.4213 2.132 to 2.747 <.0001
Social Deprivation Quintile <.0001
1 vs. 3 1.185 1.033 to 1.185 e
1 vs. 4 1.261 1.098 to 1.261 e
1 vs. 5 1.267 1.099 to 1.267 e
2 vs. 3 1.18 1.037 to 1.18 e
2 vs. 4 1.255 1.102 to 1.255 e
2 vs. 5 1.26 1.104 to 1.26 e
Strategic Health Authority .0908
Table 3. Cox proportional hazards model for 5-year all-cause
mortality in TAA patients and TAA control participants.
Covariate Hazard ratio
(>1 indicating
death is
more likely)
95% CI p
Age 1.075 1.058 to 1.093 <.0001
Gender (male vs.
female)
1.402 1.071 to 1.837 .0141
TAA (case vs.
control)
1.837 1.029 to 3.281 .0397
Comorbidity
Congestive cardiac
failure
1.451 1.02 to 2.066 .0381
Peripheral vascular
disease
2.538 1.42 to 4.545 .0017
Dementia 4.717 2.237 to 9.901 <.0001
Liver disease 2.703 1.355 to 5.405 .0048
Any malignancy 1.789 1.276 to 2.506 .0008
SHA .6131
HES year .1862
Social Deprivation Quintile .5982
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Other independent predictors of long-term mortality
included greater social deprivation, increasing age, and a
history of myocardial infarction, congestive cardiac failure,
peripheral vascular disease, cerebrovascular disease, de-
mentia, chronic pulmonary disease, rheumatological dis-
ease, liver disease, diabetes mellitus, renal disease, or
malignancy (Table 2). There was no effect of strategic health
authority, or the year of the index admission.
Multivariate analysis of survival in TAA patients and TAA
control participants revealed TAA to be an independent
predictor of poor survival in both male and female patients.Other signiﬁcant predictors of mortality were increasing
age, male gender, and a history of congestive cardiac failure,
peripheral vascular disease, dementia, liver disease, or
malignancy. There was no independent effect of strategic
health authority, year of surgery, or quintile of social
deprivation (Table 3).DISCUSSION
This analysis of a large, contemporary dataset demonstrated
that patients surviving AAA or TAA repair continue to
demonstrate considerably greater long-term morbidity and
mortality than control participants of equivalent age,
gender, and social deprivation. Although the prevalence of
AAA has fallen with improvements in public health,6,16 the
fate of patients who survive aneurysm repair is concerning
and there is considerable scope for improvement. Patients
with AAA or TAA had a signiﬁcantly higher 5-year incidence
of adverse cardiovascular events, including myocardial
infarction, stroke, emergency limb revascularisation or
amputation than control participants. Patients with aneu-
rysmal disease had a greater burden of cardiovascular, renal
and cerebrovascular comorbidity than control participants
prior to the index operation. Occlusive atherosclerosis, and
coronary artery disease in particular, is known to be
considerably more prevalent in patients with aneurysms
than the wider population.3 Systemic arterial disease is the
major cause of death and morbidity among patients with
treated AAA or TAA.1,2,17 Recognising this opportunity for
medical therapy is important because appropriate pre-
scription of antiplatelet agents, antihypertensive agents,
and statins can attain relative risk reductions of up to 75%
for preventing cardiovascular morbidity and mortality in
high-risk patients.18e24
Multivariate Cox modelling was performed for AAA pa-
tients and their control participants; and separately for TAA
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for demographics and comorbidities, TAA remained at
independently greater risk of mortality than control par-
ticipants. AAA was an independent risk factor for mortality
in female cases compared with control participants but not
in male cases, conﬁrming existing knowledge that female
patients with AAA constitute a particularly high-risk
group.25 There was no independent effect of strategic
health authority, or of the year of surgery, implying that the
shortfall in survival of patients with repaired aneurysms has
persisted in England over the study period and applies
equally to all geographical regions. The comorbidities pre-
dicting poor survival were coded as binary variables in the
administrative data used for this analysis, and it can be
hypothesised that a greater degree of comorbidity or vari-
ation in its management, might underlie the poorer survival
of patients with repaired AAA/TAA. Interestingly, this
dataset found diabetes to be signiﬁcantly more common in
patients with AAA, which is contrary to recent evidence
suggesting that diabetes may in fact have a protective role
in AAA disease.26
Increasing age was associated with poorer survival in all
patients. However, the shortfall in survival between survi-
vors of AAA repair and control participants was consistent
in octogenarians, demonstrating that the excess morbidity
and mortality of patients with aneurysms was not conﬁned
to the comparison of younger patients with their control
participants. This implies that although increasing age is
generally associated with decreased life expectancy, the
particular shortfall in survival associated with AAA (and
therefore the opportunity for improvement) applies equally
in octogenarian patients and in younger groups. The effect
was not detectable in octogenarians with TAA, but this can
almost certainly be attributed to type II error because of the
small size of this subgroup. Patients with repaired TAA had
consistently poorer survival than those with repaired AAA.
Differences in biological disease could be implicated, as TAA
are known to be associated with a greater level of circu-
lating interleukin-6 (IL-6) than AAA.27 IL-6 has been impli-
cated in the early biological processes of pathological aortic
dilatation, hypothesised to be of importance in the high
cardiovascular mortality of patients with aortic aneurysms,
identiﬁed as an independent risk factor for cardiovascular
and all-cause mortality, and circulating levels are reduced by
statin therapy.27
A limitation of the present study is that it may have
underestimated the number of cases with TAA. This was a
corollary of the decision to adopt strict inclusion criteria for
case identiﬁcation, to prevent the extraction of data per-
taining to ascending TAA repair caused by ambiguous HES
coding. A further limitation is the potential that the study
underestimated 5-year survival through exclusion of pa-
tients who died perioperatively. This strategy was chosen to
negate the effect of perioperative death on cases rather
than control participants, but it should be acknowledged
that patients who did not survive surgery might also have
had poor life expectancy without the operation. The English
data contrast with a recent report that patients survivingAAA repair attained 90% of the 5-year survival of Swedish
citizens of the same age and sex.5 In England, relative 5-year
survival was 83% following AAA repair and 73% following
TAA repair. The discrepancy in these ﬁndings might be
ascribed to the different control populations used to
compare life expectancy. The present study compared each
case with control participants that underwent surgery,
rather than to community data, which might have led to an
underestimation of the difference in survival. Further
studies should examine data across different healthcare
systems, to clarify the survival deﬁcit that is speciﬁc to
patients with repaired aneurysms. The present study
omitted patients who were turned down for aneurysm
repair28 and patients with small aneurysms in whom sur-
gery was not indicated; conclusions regarding relative sur-
vival after the repair of large AAA/TAA may not be
generalisable to these groups.
Despite the importance of cardiovascular comorbidity in
patients with an aortic aneurysm, the provision of cardio-
vascular risk prevention has not been thoroughly investi-
gated after successful AAA repair, and requires focused
research. The dataset did not permit analysis of either the
delivery or efﬁcacy of medical therapy for cardiovascular
risk management in patients with AAA/TAA; contemporary
data are needed. Cardiovascular risk management may be
particularly deﬁcient for this group compared with patients
with coronary or cerebrovascular indications for secondary
prevention; local studies suggest that as few as 40% of AAA
patients receive appropriate antiplatelet agents, statins,
angiotensin-converting enzyme inhibitors, or beta-
blockers.29 Goal-directed medical therapy has sustained
beneﬁcial effects with respect to vascular complications and
mortality in high-risk diabetic patients.4 The present study
provides compelling evidence that a comparable opportu-
nity may exist after AAA/TAA repair, despite the develop-
ment of clinical guidelines3032 and ﬁnancial incentives33
that recommend aggressive management of high cardio-
vascular risk. These initiatives have not reduced the shortfall
in long-term survival after aneurysm repair. Following
research to characterise the extent to which cardiovascular
risk is managed in patients with repaired aneurysms, a
formal trial of goal-directed intensive risk reduction therapy
might reduce the deﬁcit in survival that persists in modern
practice.CONCLUSION
The results of this study and statistical modelling corrobo-
rate known theory that the presence of greater athero-
sclerotic comorbidity is likely to underlie poorer survival in
patients with AAA and TAA. However, currently there is a
paucity of data deﬁning whether this comorbidity is modi-
ﬁable, or whether it represents an end-stage process.
Long-term survival remains poor after aneurysm repair
relative to the survival of comparable control participants.
Patients with AAA or TAA have a considerable burden of
cardiovascular comorbidity prior to operative intervention
and are at greater risk of major adverse cardiovascular
540 A. Karthikesalingam et al.events in the 5 years that follow elective surgery. The poor
relative survival of these patients has persisted despite
wider improvements in public health and incentives in
primary care to reduce cardiovascular risk. Further research
is required to characterise and optimise cardiovascular
therapy in this group.
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